53 results about "Adhesion protein" patented technology

The invention discloses a pharmaceutical composition for promoting aTreg cell differentiation and application thereof, and relates to the field of biological medicine, and the pharmaceutical composition comprises zinc salt, a basic cell culture medium, fetal calf serum, antibiotic, L-glutamine and a pH buffer agent. According to the application, the basic cell culture medium is used for providing basic nutrition required by cell growth for lymphocytes, the fetal calf serum is used for providing growth factors, hormones, adhesion proteins and nutrient substances required by cell growth for the lymphocytes, and the antibiotics are used for preventing bacterial infection; l-glutamine provides key amino acid for cell energy metabolism and participates in synthesis of protein and nucleic acid, zinc salt provides zinc ions, and under the comprehensive action, the proportion of Treg cells and aTreg cells differentiated from lymphocytes in peripheral blood mononuclear cells is increased.

The invention relates to a mytilus coruscus byssus adhesion protein gene Mfp5 coding region SNP marker and application thereof, the mytilus coruscus byssus adhesion protein gene Mfp5 coding region SNP marker comprises a gene sequence numbered as an McMfp5 coding region, the nucleotide sequence of the gene sequence is shown as SEQ ID No.1, an SNP marker primer pair is designed based on the sequence, three SNP markers numbered as McMfp51, McMfp52 and McMfp53 are obtained through sequencing, and the primer sequences of the three SNP markers are shown as SEQ ID No.2 and SEQ ID No.3 in sequence. The primer designed aiming at the gene sequence of the McMfp5 coding region is used for SNP (Single Nucleotide Polymorphism) marker typing, is high in specificity, stable in amplification and high in polymorphism, can be used for genetic diversity analysis, germplasm identification and marker-assisted selection breeding of mytilus coruscus populations, and provides a powerful tool for genetic breeding of mytilus coruscus.

The invention discloses a recombinant subunit vaccine for resisting trichomonas pigeonae infection and a preparation method of the recombinant subunit vaccine. The vaccine comprises two recombinant proteins with sequences as shown in SEQ ID NO: 7 and SEQ ID NO: 8 respectively and a pharmaceutically acceptable carrier. According to the invention, Sf9 cells are used for respectively expressing trichomonas pigeonae adhesion protein 33 and adhesion protein 65, the immunogenicity of the obtained recombinant protein is similar to that of natural protein, the expression level is high, the immunogenicity is strong, a very small amount of recombinant protein can provide a better immune protection effect, and the recombinant protein has no pathogenicity to pigeons, and can be used for preparing the recombinant protein for preventing and treating trichomonas pigeonae. Meanwhile, large-scale serum-free suspension culture can be carried out through a bioreactor, so that the vaccine production cost is greatly reduced.

The invention discloses a special membrane material for targeted trapping of macrobrachium larvae in water and a preparation method of the special membrane material, and belongs to the field of water environment biological pollution prevention and control. The membrane material is of a multi-layer composite structure and comprises a nanofiber membrane base material layer, an interface adhesion layer and a functional modification layer. The interface adhesion layer is bionic coacervate gel formed by curing hydrophobic polyelectrolyte and phytic acid; the functional modification layer is covalently grafted with a bionic adhesion protein active peptide fragment and a macrobrachium larva chemical pheromone. The material actively attracts larvae to approach through chemical pheromones, high-strength adhesion capture is achieved through bionic peptide fragments rich in aromatic and cationic amino acids, and trapping is integrated. The preparation method comprises the steps of electrostatic spinning of a base material, surface activation, gel coating, functional modification and the like. The material disclosed by the invention has high selectivity and high capture rate on the larvae of the Limnoperna fortunei, is environment-friendly, long-acting and stable, and is suitable for green prevention and treatment of fouling of the larvae of the Limnoperna fortunei in facilities such as water pipelines and pump stations.

This invention belongs to the biomedical field and relates to the application of a compound in preventing the recurrence of calcium oxalate kidney stones. The application of the compound, or its pharmaceutically acceptable salts, esters, solvates, crystal forms, or prodrugs, in the preparation of reagents for preventing the recurrence of calcium oxalate kidney stones is described. The structure of the compound is as follows: [structure details missing]. The calcium oxalate kidney stones originate from Randall plaques. Extensive experimental evidence demonstrates that Benathin can enhance intercellular adhesion by repairing the adhesion protein network damaged by hydroxyapatite (HAP), thereby reversing epithelial damage, preventing epithelial cell detachment, and effectively protecting the renal papillary mucosal barrier, thus reducing the risk of stone formation and recurrence of calcium oxalate kidney stones.

The application discloses a Mycoplasma bovum adhesion protein FtsZ and application thereof. The nucleic acid sequence of the Mycoplasma bovum adhesion protein FtsZ is shown as SEQ ID NO. 1. The application also discloses a recombinant plasmid pET-30a-ftsZ and an E. coli containing the recombinant plasmid pET-30a-ftsZ. ftsZ The recombinant protein rFtsZ has the advantages of being capable of specifically combining with EBL cell membrane protein, being capable of combining with extracellular matrix components (fibronectin, fibronectin, laminin and type IV collagen), having the direct adhesion host cell effect, having good antigenicity, being capable of producing high-level antibodies, being capable of providing good immune protection effect, and providing a new target and thought for elucidating the pathogenic mechanism of the Mycoplasma bovum and developing a new vaccine and medicine.

An object is to provide a PHA production method which enables efficient filtration. The above problem is solved by providing a PHA production method including a filtration step of subjecting, to dead-end filtration, an aqueous PHA suspension having a pH of 2.5 to 5.5 with use of a filter medium having an air permeability of 0.01 cc / cm2 / sec to 5.0 cc / cm2 / sec, the aqueous PHA suspension containing PHA surface adhesion protein in an amount of not more than 2,000 ppm, the aqueous PHA suspension having a liquid density of 0.50 g / mL to 1.08 g / mL in the filtration step.

The present invention discloses a composite skull repair hydrogel material with a patterned adhesion-promoting surface and a preparation method thereof. The preparation method comprises the following: 1) using a precipitation method to prepare mesoporous manganese dioxide (MMD), then combining a cyclic ultrasonic loading method to load osteogenic drugs in the pores of the MMD, and using an in-situ free radical polymerization method to coat a sustained-release polydopamine (PDA) coating on its surface to obtain MMD-O-PDA; 2) MMD-O-PDA is evenly mixed with an amino-containing UV-curable polymer solution, placed on a custom PDMS mold with a special patterned surface, covered with a transparent quartz sheet, and UV-cured and demolded; 3) in situ grafting of adhesion proteins on the surface of the composite hydrogel material with a cross-linking agent, and the hydrogel material is obtained after ultra-frequency dialysis. The material has a highly efficient cell adhesion-promoting effect, can quickly enrich osteoblasts in the defect site, and simultaneously has anti-inflammatory and full-cycle osteogenic effects, thereby efficiently promoting the repair of skull defect sites.

The invention relates to an application abstract of IFIT5 protein or a coding gene thereof in regulation and control of poultry immune response. The invention belongs to the technical field of biology, and particularly relates to an application of chicken IFIT5 protein or a coding gene thereof in regulation and control of poultry immune response. Through transcriptome sequencing of MG infected cells and chicken lung tissues, the IFIT5 gene expression quantity is found to be remarkably increased. Through overexpression of the IFIT5 gene in chicken macrophages, it is found that the IFIT5 effectively inhibits MG proliferation and adhesion protein expression by activating I-type interferon, the resistance of poultry to MG is improved, and the IFIT5 can be applied to treatment of MG or used as a disease-resistant molecular marker. In addition, the dynamic change of IFIT5 in chicken primary alveolar type II epithelial cells and macrophages is related to the MG infection process, and a new target is provided for early diagnosis of MG. The discovery provides an important theoretical basis for MG diagnosis, MG prevention and poultry disease resistance breeding.

This disclosure provides antibodies that bind to human adhesion G protein-coupled receptor B1 (BAI1) protein, compositions comprising said antibodies, and their use in detection, diagnostic, and therapeutic methods. Sequences of complementarity-determining regions (CDRs) in the variable heavy chain (VH) and variable light chain (VL) sequences, as well as the amino acid sequences of VH and VL, are also provided.

A process (1) for producing an article (2) from a plant-based material (3) includes providing (4) genetically modified microorganisms (5) in which the genetic modification (12) results in overexpression of at least one adhesive protein (6); mixing (7), preferably blending, of the plant-based material (3) with the genetically modified microorganisms (5), which are preferably held in a culture medium (11), to obtain a mixture (8); expressing of the adhesive protein (6); and hardening (10) of the mixture (8).

Provided is an immunogenic Mycoplasma pneumoniae polypeptide epitope, which is a polypeptide epitope derived from the key adhesion proteins P1, P30, P40 / 90 and P116 of type I and type II Mycoplasma pneumoniae, and / or the CARDS toxin thereof. Further provided is a recombinant protein, which contains one or more of the immunogenic Mycoplasma pneumoniae polypeptide epitopes. Further provided is a vaccine for preventing Mycoplasma pneumonia infections, which vaccine provides protection against at least one of type I and / or type II Mycoplasma pneumonia infections, and is characterized in that the vaccine contains the recombinant protein and is a vaccine capable of providing safe and effective protection against Mycoplasma pneumonia infections.

The present invention relates to a diagnostic composition comprising at least one peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1 (VDELERIRRSILPYGDSMDRIEKDR), SEQ ID NO: 2 (GGAGSLGAGGAFGEA), SEQ ID NO: 35 (GPAGPPGHPGPPGPR), SEQ ID NO: 4 (EGLITLTELADSLLS), SEQ ID NO: 5 (EFQYLTGGLIEPQVH), SEQ ID NO: 6 (SSHMLTDTKTGLHFN), SEQ ID NO: 7 (FIPGPPGPPGPPGPR), SEQ ID NO: 8 (INEAIEQGTIDKALV), SEQ ID NO: 9 (AFGEAAGDRGPYGTDI) and SEQ ID NO: 10 (LITLTELADSLLSRL). Furthermore, the present invention relates to an in vitro method for detecting the presence or absence of a disease selected from the group of bullous pemphigoid, Parkinson's disease, and a neurological disorder comprising testing the binding of at least one peptide as identified in any of the preceding claims for binding to autoantibodies obtained from a subject suspected of suffering from one of said diseases.

The present invention discloses a Pichia pastoris genetically engineered bacterium with efficient surface display of enzymes based on adhesion proteins, a construction method thereof, and an application in immobilized continuous catalysis. Adhesion protein genes, β-galactosidase gene LacA, and cell wall anchor protein gene Pir1p are heterologously expressed in the starting strain Pichia pastoris. The Pichia pastoris genetically engineered bacterium integrates and expresses the cell wall adhesion protein gene in the Pichia pastoris GS115 genome, significantly enhancing the film-forming ability of the Pichia pastoris cells; then, multiple copies of the β-galactosidase surface display gene are integrated, and a constitutive promoter is used to control the display of the target protein β-galactosidase on the yeast surface. The Pichia pastoris genetically engineered bacterium with efficient surface display of enzymes based on adhesion proteins can carry out multiple batches of continuous catalysis and has better effects than enzyme surface display genetically engineered bacteria without integrated biofilm genes. After 6 batches, the relative conversion rate still remains at 78%, which has good prospects for industrial application in immobilized continuous catalysis.

An antiviral coating composition is provided. An antiviral coating composition according to one embodiment of the present invention is implemented by including an antiviral component comprising an antiviral fusion protein in which an antiviral motif is bound to an adhesive protein. According to the present invention, the composition has excellent processability enabling easy provision on various surfaces of various products, has adhesion sustainability enabling an adhesive state to be maintained for a long period of time after being adhered to a surface, and has activity sustainability enabling antiviral activity to be maintained for a long period of time without a loss in activity according to external conditions during preparation, storage and use.

The construction method comprises the following steps: amplifying a Cwp8 protein gene on a clostridium difficile genome, constructing the Cwp8 protein gene on a pLEB124 plasmid to obtain a recombinant plasmid pLEB124-Cwp8, and transferring the recombinant plasmid pLEB124-Cwp8 into lactococcus lactis F44 to obtain the clostridium difficile resistant lactococcus lactis, which is named as Lla-Cwp8, and the clostridium difficile resistant lactococcus lactis is named as Lla-Cwp8, and the clostridium difficile resistant lactococcus lactis is named as Lla-Cwp8. The surface of the Lla-Cwp8 disclosed by the invention can express the adhesion protein and realize high yield of Nisin. Experiments prove that Lla-Cwp8 has strong competition, rejection and translocation capabilities on clostridium difficile in vitro, can effectively reduce the survival rate of clostridium difficile and reduce colon shortening in vivo, can significantly reduce the expression of virulence proteins TcdA and TcdB and the expression of immune factors TNF-alpha and IL-6, and has a treatment effect on clostridium difficile infection.

The application discloses a NEED short peptide modified polylactic acid implant material and a preparation method and application thereof, and relates to the technical field of biomedical materials. The preparation method of the NEED short peptide modified polylactic acid implant material provided by the application is as follows: an interface composed of polylactic acid material is constructed on the surface of an implant material substrate, the interface is activated, and the NEED short peptide is fixed on the interface. The polylactic acid implant material prepared by the application utilizes the interface composed of the polylactic acid material and the NEED short peptide with negative electricity to enhance the adhesion stability of adhesion proteins such as fibronectin and to enhance the subsequent cell adhesion response, thereby promoting cell adhesion and implant material integration. The material can be widely applied to the fields of degradable vascular stents, bone repair materials, dental implants, tissue engineering stents and nanofiber membranes, and can also provide a new technical scheme for interface functionalization of implant materials in a metabolic abnormal environment, and has a wide application prospect.

The present invention provides a chimeric or fusion protein for inducing an immune response to P. gulae, the protein comprising a first polypeptide and a second polypeptide, wherein: A) the first polypeptide comprises or consists of an amino acid sequence of the active site of an Arg- or Lys-gingipain of P. gulae, or a sequence that is at least 80% identical thereto; and B) the second polypeptide comprises or consists of: the amino acid sequence of a DUF2436 domain of a P. gulae Arg- or Lys-gingipain; and the amino acid sequence of an adhesin domain of an Arg- or Lys-gingipain of P. gulae.

The invention discloses a mytilus coruscus byssus adhesion protein mutant, application thereof and a method for identifying phenotypic characters of mytilus coruscus byssus, and relates to the technical field of biology. The amino acid sequence of the mytilus coruscus byssus adhesion protein mutant is as shown in SEQ ID NO. 4. In-depth study shows that non-synonymous mutation of a mytilus coruscus Mfp3-6 gene coding region can directly influence functional characteristics of protein, so that a clear causal relationship is established between a genotype and a mytilus coruscus byssus adhesion performance phenotype. The invention further provides a mytilus coruscus byssus adhesion protein mutant. The mytilus coruscus byssus adhesion protein mutant has an excellent adhesion strength characteristic, so that the mytilus coruscus byssus adhesion protein mutant has a wide application prospect in the field of functional adhesion materials. The protein mutant can be widely applied to development of materials such as medical glue, dressing and gel, provides important technical support for research and development of bionic adhesion technology and novel biological materials, and has good industrialization potential and social value.

The invention belongs to the technical field of genetic engineering, and provides an application of gga-miR-1783 in resisting infection of mycoplasma gallisepticum (MG) in poultry, and provides a preparation method of the gga-miR-1783 for resisting infection of mycoplasma gallisepticum (MG) in poultry. The invention finds that the expression quantity of the gga-miR-1783 in the spleen of a mycoplasma gallisepticum infected group is obviously lower than that of a control group. When the gga-miR-1783 is over-expressed in chicken macrophages (HD11), the replication of mycoplasma gallisepticum in cells and the expression of adhesion protein pMGA1.2 can be effectively inhibited, MG-induced inflammatory response and cell apoptosis are inhibited, cell proliferation is promoted, and the MG infection resistance is remarkably improved. The expression of the gga-miR-1783 disclosed by the invention can be induced through genetic engineering, or the miRNA is directly injected to improve the MG infection resistance of the chicken, and the gga-miR-1783 can also be used as a molecular marker or target spot for resisting mycoplasma gallisepticum infection of the chicken, and has important practical value in genetic-assisted disease-resistant breeding and disease prevention and treatment.

A chimeric or fusion protein for inducing an immune response to P. gingivalis, the protein comprising a first polypeptide linked to a second polypeptide, wherein: A) the first polypeptide comprises or consists of an amino acid sequence of the active site of an Arg- or Lys-gingipain of P. gingivalis, or a sequence that is at least 80% identical thereto; and B) the second polypeptide comprises or consists of an amino acid sequence of an adhesin domain of an Arg- or Lys-gingipain of P. gingivalis; and wherein the second polypeptide: a) comprises an amino acid sequence corresponding substantially to the full length of the DUF2436 domain of an Arg- or Lys-gingipain, or a sequence at least 80% identical thereto; and / or b) comprises one or more cysteine amino acid substitutions in the adhesin domain, compared to the naturally occurring Arg- or Lys-gingipain sequences in corresponding regions; and optionally comprises one or more amino acid motif substitutions in the adhesin domain for reducing multimerisation.

The present disclosure provides a pharmaceutical association comprising at least one growth factor receptor-binding compound, which activates at least one growth factor receptor of a neoplastic cell, and at least one adhesion protein inhibitor which inhibits at least one transmembrane cell adhesion protein of said neoplastic cell.

The application discloses a triplex forming oligonucleotide fluorescent probe and a detection method for detecting mycoplasma by targeting P1 adhesion protein genes, and belongs to the technical field of microbial molecular detection. The fluorescent probe is a triplex forming oligonucleotide (TFO), targets a specific conservative sequence of mycoplasma P1 adhesion protein genes, the 5' end of the fluorescent probe is modified with a fluorescent reporter group, the 3' end of the fluorescent probe is modified with a fluorescent quenching group, the fluorescent probe can form a stable triplex DNA complex with the target sequence through Hoogsteen base pairing and generate a fluorescent signal. The detection method comprises four core steps of sample pretreatment and DNA extraction, fluorescent probe incubation, fluorescent signal detection and result judgment, and does not need PCR amplification, and is simple in operation and rapid in detection. The probe has high specificity and high sensitivity, the detection lower limit can reach 1 copy / muL, is suitable for mycoplasma detection of various types of samples, and can be widely applied to scenes such as clinical diagnosis, biological pharmaceutical quality control and livestock breeding quarantine.

The invention belongs to the field of biomedicine, and relates to application of a compound in preventing relapse of calcium oxalate kidney stone. The invention relates to application of the compound or pharmaceutically acceptable salt, ester, solvate, crystal form or prodrug thereof in preparation of a reagent for preventing relapse of calcium oxalate kidney stone. The structure of the compound is shown in the specification; the calcium oxalate kidney stone is derived from a Randall plaque. A large number of experiments prove that Benarthin can repair an adhesion protein network damaged by hydroxyapatite HAP, so that intercellular adhesion is enhanced, epithelial injury is reversed, epithelial cells are prevented from falling off, and a renal papilla mucous membrane barrier is effectively protected, so that the risk of calculus formation and relapse of calcium oxalate kidney calculus is reduced.

Compositions and methods for mucosal delivery of agents are provided. The emulsion compositions are intended for administration to a mucosal surface, such as oral, gastrointestinal and nasal mucosa. The emulsion compositions provided contain one or more mucoadhesive proteins and an agent to be delivered. Methods for delivery of agents using the compositions provided herein are also provided.

The application belongs to the field of biotechnology, and particularly relates to a Mycoplasma bovum adhesion protein P24 and application thereof. A novel Mycoplasma bovum adhesion protein is identified by various biological and immunological methods, the protein can promote the combination of Mycoplasma bovum and host cells, and further research shows that the protein realizes the adhesion function by combining with heparin. In addition, the polyclonal antibody against the P24 protein can obviously inhibit the adhesion of Mycoplasma bovum to host cells, and the adhesion function is closely related to bacterial virulence. An effective target is provided for the development of novel vaccines, diagnostic and therapeutic preparations.

The present invention provides a recombinant human Mycoplasma pneumoniae adhesion protein vaccine comprising human Mycoplasma pneumoniae adhesion proteins P1, P30, P40 / 90, and P116 fusion proteins C1, C1-G4S, C2, and C2-G4S. Upon immunization of mice with the recombinant human Mycoplasma pneumoniae adhesion protein vaccine, purified and expressed in Escherichia coli, the vaccine induces a strong immune response in vivo, reduces cytokine production, and reduces Mycoplasma pneumoniae colonization in lung tissue. The vaccine can be used for the prevention, detection, or treatment of Mycoplasma pneumoniae infection.

There is provided topical pharmaceutical formulations comprising montelukast, or a pharmaceutically acceptable salt of solvate thereof, as well as combination products comprising (a) at least one mussel adhesive protein or a derivative thereof; and (b) montelukast, or a pharmaceutically-acceptable salt or solvate thereof. The formulations and combination products find particular utility in direct topical administration for the treatment of inflammation, of inflammatory disorders and / or of condition characterized by inflammation, including wounds, burns, psoriasis, acne and atopic dermatitis.

Provided is an adhesive protein that has high adhesive strength and low toxicity and can be efficiently produced. In addition, there is provided an adhesive protein having adhesiveness and additional functionality useful for medical and / or research applications. A recombinant protein includes a functional peptide portion having growth factor activity; and an adhesive peptide portion fused to an N-terminal side and an adhesive peptide portion fused to a C-terminal side of the functional peptide portion.

The present invention provides a bio-nanoshell for binding specifically to a target cell. The bio-nanoshell may comprise a cell-derived biological membrane from a donor cell and a nanoshell having an exterior surface coated with the cell-derived biological membrane. The cell-derived biological membrane may comprise a phospholipid bilayer and an adhesion protein specific for the target cell. Also provided is a method for preparing the bio-nanoshells and a method for delivering the bio-nanoshells to target cells.